Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 2:25 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2713–2736 of 3,983 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Pathophysiology Clear all

Conditions: Menopause, Elevated Blood Pressure, Hypertension, Endothelial Dysfunction
Interventions: Blueberry Powder, Placebo Powder; Dietary Supplement
Lead sponsor: Colorado State University; Other
Eligibility: 45 Years to 65 Years · Female only
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Cachexia, Pancreatic Cancer
Interventions: immunologic technique, laboratory biomarker analysis, biopsy; Other · Procedure
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Alzheimer Disease, Late Onset, Mild Cognitive Impairment, Sleep, Cognitive Change, Amyloid
Interventions: Time in Bed Restriction, Sleep Schedule; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 65 Years to 85 Years
Enrollment: 99 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Vulvovaginal Atrophy, Menopause, Dyspareunia
Interventions: Estradiol Vaginal Capsule (EVC), Placebo; Drug
Lead sponsor: Warner Chilcott; Industry
Eligibility: 35 Years and older · Female only
Enrollment: 203 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 20
States / cities: Tucson, Arizona • San Diego, California • New London, Connecticut + 17 more

Conditions: Type 2 Diabetes Mellitus, Obesity
Interventions: Roux-en-Y Gastric Bypass Surgery, Laparoscopic Adjustable Gastric Banding, Lifestyle Weight Loss Intervention; Procedure · Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 25 Years to 55 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2028
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Seizure Disorder, Hypogonadism, Erectile Dysfunction
Interventions: Anastrozole 1mg, Placebo Oral Tablet; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Sacroiliac Joint Dysfunction
Interventions: SImmetry Sacroiliac Fusion System; Device
Lead sponsor: Zyga Technology, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Reno, Nevada

Conditions: Urology, Urinary Bladder, Overactive, Benign Prostatic Hyperplasia, Urodynamics, Home Monitoring, Urinary Incontinence (UI), Lower Urinary Tract Dysfunction
Interventions: Glean Urodynamics System; Device
Lead sponsor: Bright Uro; Industry
Eligibility: 22 Years and older
Enrollment: 101 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 9
States / cities: New Orleans, Louisiana • Hanover, Maryland • Owings Mills, Maryland + 6 more

Conditions: Mild Cognitive Impairment
Interventions: Kodro+, Kodro+D; Other
Lead sponsor: Mt. Sinai Medical Center, Miami; Other
Eligibility: 60 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Miami Beach, Florida

Conditions: Alzheimer's Disease, Behavioral Variant Frontotemporal Dementia
Interventions: LMTM; Drug
Lead sponsor: TauRx Therapeutics Ltd; Industry
Eligibility: Not listed
Enrollment: 913 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 57
States / cities: Phoenix, Arizona • Fountain Valley, California • Laguna Hills, California + 48 more

Conditions: Atrial Fibrillation, Atrial Flutter, Heart Block, Pulmonary Embolism and Thrombosis, Mitral Valve Repair, Sinus Node Dysfunction, Bradycardia, Brady-tachy Syndrome
Interventions: Perclose ProGlide Suture-Mediated Closure System (SMC) - LARGE-BORE PROCEDURES, Figure 8 Suture - LARGE-BORE PROCEDURES; Device · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Mild Cognitive Impairment, Mild Alzheimer's Disease
Interventions: PET scan & fMRI; Other
Lead sponsor: Louisiana State University Health Sciences Center Shreveport; Other
Eligibility: 55 Years to 85 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Shreveport, Louisiana

Conditions: Cognitive Impairment, Cardiac Disease, Heart Failure
Interventions: Not listed
Lead sponsor: Kent State University; Other
Eligibility: 55 Years to 85 Years
Enrollment: 372 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2010
U.S. locations: 1
States / cities: Akron, Ohio

Conditions: Corneal Edema, Fuchs, Fuchs Dystrophy, Fuchs' Endothelial Dystrophy, Endothelial Corneal Dystrophy, Corneal Endothelial Decompensation, Corneal Endothelial Cell Loss, Corneal Endothelial Disorder, Corneal Endothelial Dystrophy 1, Endothelial Cell Loss, Corneal, Pseudophakic Bullous Keratopathy, Pseudophakic Bullous Keratopathy (PBK)
Interventions: 150K cells, 500K cells, Placebo; Biological · Procedure
Lead sponsor: Emmecell; Industry
Eligibility: 21 Years and older
Enrollment: 121 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 10
States / cities: Torrance, California • Largo, Florida • Atlanta, Georgia + 7 more

Conditions: Diabetic Foot Ulcers
Interventions: Prevention Diabetic Foot Ulcer; Device
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2002
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Erectile Dysfunction
Interventions: moxifloxacin, avanafil, sugar pill; Drug
Lead sponsor: VIVUS LLC; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Ovulatory Dysfunction, Anovulation, Ovulation Induction
Interventions: clomiphene citrate; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Posterior Tibial Tendon Dysfunction
Interventions: Bracing, Strengthening exercises, Stretching exercises; Device · Other
Lead sponsor: Ithaca College; Other
Eligibility: 40 Years to 80 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Rochester, New York

Conditions: HIV Infections
Interventions: Oral BMS-663068 (pro-drug); Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Postoperative Gastrointestinal Dysfunction
Interventions: Naldemedine, Placebo; Drug
Lead sponsor: Shionogi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 8
States / cities: Tucson, Arizona • Louisville, Kentucky • Houston, Texas + 1 more

Conditions: Castration-Resistant Prostatic Cancer, Metastatic Prostate Carcinoma, Recurrent Prostate Carcinoma, Stage IV Prostate Cancer, Hormone-Refractory Prostate Cancer
Interventions: GnRH agonist/antagonist, Prednisone, Abiraterone Acetate, Enzalutamide; Biological · Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older · Male only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2029
U.S. locations: 5
States / cities: Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 2 more

Conditions: Granulomatous Disease, Chronic
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 1,480 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2021
U.S. locations: 39
States / cities: Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 34 more

Conditions: Covid19
Interventions: Placebo, Fisetin; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma, Metastatic Malignant Solid Neoplasm, Stage III Hepatocellular Carcinoma AJCC v7, Stage IIIA Hepatocellular Carcinoma AJCC v7, Stage IIIB Hepatocellular Carcinoma AJCC v7, Stage IIIC Hepatocellular Carcinoma AJCC v7, Stage IV Hepatocellular Carcinoma AJCC v7, Stage IVA Hepatocellular Carcinoma AJCC v7, Stage IVB Hepatocellular Carcinoma AJCC v7, Unresectable Solid Neoplasm
Interventions: Laboratory Biomarker Analysis, Pharmacological Study, Tazemetostat; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Blueberries for Improving Vascular Endothelial Function in Postmenopausal Women With Elevated Blood Pressure

Biological Markers in Patients With Pancreatic Cancer Experiencing Weight Loss

Time-in-bed Restriction in Older Adults With Sleep Difficulties With and Without Risk for Alzheimer's Disease

A Safety and Efficacy Study of Estradiol Vaginal Capsule in Postmenopausal Women With Vulvovaginal Atrophy

The TRIABETES - ARMMS-T2D Study: A Randomized Trial to Compare Surgical and Medical Treatments for Type 2 Diabetes

Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo

SI Joint Fusion and Decortication Using the SImmetry System

Ambulatory Long Length URodynamics Evaluation

The Effect of a 36-week Tablet-based Intervention on Multiple Domains in Older Adults With Mild Cognitive Impairment

Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)

Suture Closure AFtEr VEIN Access for Cardiac Procedures (SAFE-VEIN) Trial

Early Detection of Mild Cognitive Impairment in Individual Patients

Self-management and Cognitive Function in Adults With Heart Failure

Study of EO2002 in Subjects With Corneal Edema Secondary to Corneal Endothelial Dysfunction

A Prospective Study of Endothelial Dysfunction and Diabetic Foot Ulcer Risk

A Thorough EKG Safety Study of TA-1790 (Avanafil)

Traditional Clomiphene Citrate Administration vs. Stair-step Approach

Bracing and Strengthening for Posterior Tibial Tendon Dysfunction

A Study of the Pharmacokinetics and Safety of BMS-663068 Administered in Subjects With Normal Renal Function and With Mild, Moderate, Severe and End Stage Renal Dysfunction (ESRD)

A Study of Naldemedine in Participants Undergoing Surgeries That Include a Bowel Resection or Bowel Transection

Cognitive Effects of Androgen Receptor Directed Therapies for Advanced Prostate Cancer

Patients Treated for Chronic Granulomatous Disease (CGD) Since 1995

COVID-FISETIN: Pilot in SARS-CoV-2 of Fisetin to Alleviate Dysfunction and Inflammation

Tazemetostat in Treating Patients With Metastatic or Unresectable Solid Tumors or B-Cell Lymphomas With Liver Dysfunction